Press Releases Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
34.48 ^USD	+0.12%		+9.36%	+6.16%

Jun. 04	Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	Jun. 06	AQ
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)	Jun. 03	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients with Hypercortisolism	May. 29	AQ
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	GL
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)	May. 28	AQ
Corcept: Q1 Earnings Snapshot	May. 01	AQ
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	May. 01	AQ
Corcept Completes Enrollment in Phase 4 CATALYST Trial	Apr. 29	GL
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	Apr. 24	GL
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome	Apr. 23	AQ
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome	Apr. 22	GL
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)	Apr. 15	GL
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	GL
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome	Apr. 01	GL
Corcept: Q4 Earnings Snapshot	Feb. 15	AQ
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update	Feb. 15	GL
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial	Feb. 15	GL
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call	Feb. 08	GL
When Does A Drug Label Induce Infringement Under 35 U.S.C. § 271(e)(2) Of A Patent Not Claiming An Indication Or Method Of Use?	Jan. 31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Press Releases

Filters